March 9, 2020 / 11:32 AM / 19 days ago

BRIEF-Bristol-Myers' multiple myeloma combo therapy fails late-stage study

March 9 (Reuters) - Bristol-Myers Squibb Co:

* BRISTOL MYERS SQUIBB REPORTS PRIMARY RESULTS OF ELOQUENT-1 STUDY EVALUATING EMPLICITI (ELOTUZUMAB) PLUS REVLIMID (LENALIDOMIDE) AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED, UNTREATED MULTIPLE MYELOMA

* BRISTOL-MYERS SQUIBB CO - PHASE 3 TRIAL DID NOT MEET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL IN PATIENTS NOT ELIGIBLE FOR TRANSPLANT

* BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF ERD WAS GENERALLY CONSISTENT WITH KNOWN PROFILE OF EMPLICITI PLUS REVLIMID AND DEXAMETHASONE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below